Sharp Therapeutics plans non-brokered private placement raising up to C$1.37 million at minimum C$0.91/share

• Sharp Therapeutics launched a non-brokered private placement to raise up to C$ 1.37 million through common shares priced at no less than C$ 0.91.
• Closing targeted for Q3 2026; proceeds earmarked for general working capital.
• Chairman William R. Newlin, via Newlin Investment Company 1, plans to invest about US$ 200,000 on the same terms.
• Strategic shift to an alternative lead candidate expected to push certain funding needs out by 6-12 months.
• STX Partners financing discussions ended, terminating a previously announced proposal for up to about US$ 10 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sharp Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202607150800NEWSFILECNPR____20260715_305226_1) on July 15, 2026, and is solely responsible for the information contained therein.